Inspire Investing’s AstraZeneca AZN Stock Holding History

Inspire Investing’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.67K	Hold	14	–	–	﹤0.01%	1149
2026 Q1	$2.77K	Hold	14	–	–	﹤0.01%	996
2025 Q4	$2.56K	Buy	+14	New	+$2.46K	﹤0.01%	978
2021 Q3	–	Sell	-18,558	Closed	-$2.22M	–	807
2021 Q2	$2.22M	Buy	+18,558	New	+$2.04M	0.29%	74

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Inspire Investing's AZN Position: Q2 2026 in Review

Inspire Investing held its AstraZeneca (AZN) position steady in Q2 2026 at 14 shares worth $2.67K. The position accounts for ﹤0.01% of the portfolio, ranked #1149.

Inspire Investing first reported a position in AZN in Q2 2021 and has held it in 4 quarters since. The position peaked at $2.22M in Q2 2021. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Inspire Investing held 14 shares of AstraZeneca worth $2.67K as of Q2 2026.
Inspire Investing left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up ﹤0.01% of Inspire Investing's portfolio in Q2 2026, its #1149 holding.
Inspire Investing first reported a position in AstraZeneca in Q2 2021 and has held it in 4 quarters since.
Inspire Investing's AstraZeneca position peaked at $2.22M in Q2 2021.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Inspire Investing's 13F filing for Q2 2026, filed 12 Aug 2026.